Page 1 | Search Results | Diabetes Care | American Diabetes Association

1-20 of 24

Sort by

Sort Order Select

Journal Articles

Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations

Francesco Rubino, David M. Nathan, Robert H. Eckel, Philip R. Schauer, K. George M.M. Alberti, Paul Z. Zimmet, Stefano Del Prato, Linong Ji, Shaukat M. Sadikot, William H. Herman, Stephanie A. Amiel, Lee M. Kaplan, Gaspar Taroncher-Oldenburg, David E. Cummings, Delegates of the 2nd Diabetes Surgery Summit, Nizar Albache, Rachel L. Batterham, Deepak L. Bhatt, Camilo Boza, William T. Cefalu, Ricardo V. Cohen, Anita P. Courcoulas, Sean F. Dinneen, John B. Dixon, Ele Ferrannini, Paola Fioretto, Gema Frühbeck, Michel Gagner, Richard W. Grant, Sayeed Ikramuddin, Desmond G. Johnston, Sangeeta R. Kashyap, Tracy Kelly, Tomasz Klupa, Judith Korner, Blandine Laferrère, Harold E. Lebovitz, Wei-Jei Lee, Carel W. le Roux, Jeffrey I. Mechanick, Geltrude Mingrone, John M. Morton, Walter J. Pories, Robert E. Ratner, Gerry Rayman, Harvey J. Sugerman, Luc Van Gaal, Josep Vidal, Jianping Weng, Bruce M. Wolfe

Diabetes Care 2016;39(6):861–877

https://doi.org/10.2337/dc16-0236

Published: 13 May 2016

View article titled, Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations

Includes: Supplementary data

Journal Articles

The Efficacy and Safety of Imeglimin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Sitagliptin Monotherapy

Pascale Fouqueray, Valdis Pirags, Michaela Diamant, Guntram Schernthaner, Harold E. Lebovitz, Silvio E. Inzucchi, Clifford J. Bailey

Diabetes Care 2014;37(7):1924–1930

https://doi.org/10.2337/dc13-2349

Published: 12 June 2014

View article titled, The Efficacy and Safety of Imeglimin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Sitagliptin Monotherapy

Includes: Supplementary data

Journal Articles

The Efficacy and Safety of Imeglimin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy

Pascale Fouqueray, MD, Valdis Pirags, MD, Silvio E. Inzucchi, MD, Clifford J. Bailey, PHD, Guntram Schernthaner, MD, Michaela Diamant, MD, Harold E. Lebovitz, MD

Diabetes Care 2013;36(3):565–568

https://doi.org/10.2337/dc12-0453

Published: 13 February 2013

View article titled, The Efficacy and Safety of Imeglimin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy

Journal Articles

Insulin: Potential Negative Consequences of Early Routine Use in Patients With Type 2 Diabetes

Harold E. Lebovitz, MD

Diabetes Care 2011;34(Supplement_2):S225–S230

https://doi.org/10.2337/dc11-s225

Published: 22 April 2011

View article titled, Insulin: Potential Negative Consequences of Early Routine Use in Patients With Type 2 Diabetes

Journal Articles

Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A Consensus Statement From the American Diabetes Association and the European Association for the Study of Diabetes : Response to Nathan et al.

Paul S. Jellinger, MD, MACE, Harold E. Lebovitz, MD, FACE, Jaime A. Davidson, MD, FACE, on behalf of the ACE/AACE Outpatient Glycemic Control Implementation Task Force

Diabetes Care 2007;30(4):e16–e17

https://doi.org/10.2337/dc06-2373

Published: 01 April 2007

View article titled, Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A Consensus Statement From the American Diabetes Association and the European Association for the Study of Diabetes : <subtitle>Response to Nathan et al.</subtitle>

Journal Articles

Point: Visceral Adiposity Is Causally Related to Insulin Resistance

Harold E. Lebovitz, MD, Mary Ann Banerji, MD, FACP

Diabetes Care 2005;28(9):2322–2325

https://doi.org/10.2337/diacare.28.9.2322

Published: 01 September 2005

View article titled, Point: Visceral Adiposity Is Causally Related to Insulin Resistance

Journal Articles

Evaluation of Liver Function in Type 2 Diabetic Patients During Clinical Trials: Evidence that rosiglitazone does not cause hepatic dysfunction

Harold E. Lebovitz, MD, Margaret Kreider, PHD, Martin I. Freed, MD

Diabetes Care 2002;25(5):815–821

https://doi.org/10.2337/diacare.25.5.815

Published: 01 May 2002

View article titled, Evaluation of Liver Function in Type 2 Diabetic Patients During Clinical Trials: <subtitle>Evidence that rosiglitazone does not cause hepatic dysfunction</subtitle>

Journal Articles

Hyperfiltration in African-American Patients With Type 2 Diabetes: Cross-sectional and longitudinal data

Rochelle L Chaiken, MD, Margaret Eckert-Norton, MS, FNP, Mara Bard, MD, Mary Ann Banerji, MD, Joanne Palmisano, MD, Isaac Sachimechi, MD, Harold E Lebovitz, MD

Diabetes Care 1998;21(12):2129–2134

https://doi.org/10.2337/diacare.21.12.2129

Published: 01 December 1998

View article titled, Hyperfiltration in African-American Patients With Type 2 Diabetes: Cross-sectional and longitudinal data

Journal Articles

Response to Nagasaka et al: Ketoacidosis-onset type 2 diabetes: clinical features and implicatio

Harold E Lebovitz, MD, Samy McFarlane, MD, Mary Ann Banerji, MD

Diabetes Care 1998;21(8):1377–1378

https://doi.org/10.2337/diacare.21.8.1377

Published: 01 August 1998

View article titled, Response to Nagasaka et al: Ketoacidosis-onset type 2 diabetes: clinical features and implicatio

Journal Articles

Utility of Untimed Urinary Albumin Measurements in Assessing Albuminuria in Black NIDDM Subjects

Rochelle L Chaiken, MD, Raheela Khawaja, MD, Mara Bard, MS, Margaret Eckert-Norton, MS, FNP, CDE, Mary Ann Banerji, MD, Harold E Lebovitz, MD

Diabetes Care 1997;20(5):709–713

https://doi.org/10.2337/diacare.20.5.709

Published: 01 May 1997

View article titled, Utility of Untimed Urinary Albumin Measurements in Assessing Albuminuria in Black NIDDM Subjects

Journal Articles

Stepwise and Combination Drug Therapy for the Treatment of NIDDM

Harold E Lebovitz, MD

Diabetes Care 1994;17(12):1542–1544

https://doi.org/10.2337/diacare.17.12.1542

Published: 01 December 1994

View article titled, Stepwise and Combination Drug Therapy for the Treatment of NIDDM

Journal Articles

HLA-DQ Associations Distinguish Insulin-Resistant and Insulin-Sensitive Variants of NIDDM in Black Americans

Mary Ann Banerji, MD, Allen J Norin, PHD, Rochelle L Chaiken, MD, Harold E Lebovitz, MD

Diabetes Care 1993;16(2):429–433

https://doi.org/10.2337/diacare.16.2.429

Published: 01 February 1993

View article titled, HLA-DQ Associations Distinguish Insulin-Resistant and Insulin-Sensitive Variants of NIDDM in Black Americans

Journal Articles

Insulin Action in Black Americans With NIDDM

Mary Ann Banerji, MD, Harold E Lebovitz, MD

Diabetes Care 1992;15(10):1295–1302

https://doi.org/10.2337/diacare.15.10.1295

Published: 01 October 1992

View article titled, Insulin Action in Black Americans With NIDDM

Journal Articles

Patterns of Glucose and Lipid Abnormalities in Black NIDDM Subjects

Rochelle L Chaiken, MD, Mary Ann Banerji, MD, RoseMarie Pasmantier, MD, Howard Huey, DO, Sondra Hirsch, RN, Harold E Lebovitz, MD

Diabetes Care 1991;14(11):1036–1042

https://doi.org/10.2337/diacare.14.11.1036

Published: 01 November 1991

View article titled, Patterns of Glucose and Lipid Abnormalities in Black NIDDM Subjects

Journal Articles

Cross-Sectional Analysis of Renal Function in Black Americans With NIDDM

Harold E Lebovitz, MD, JoAnne Palmisano, MD

Diabetes Care 1990;13(11):1186–1190

https://doi.org/10.2337/diacare.13.11.1186

Published: 01 November 1990

View article titled, Cross-Sectional Analysis of Renal Function in Black Americans With NIDDM

Journal Articles

Introduction

Diabetes Care 1990;13(Supplement_3):1

https://doi.org/10.2337/diacare.13.3.1

Published: 01 August 1990

View article titled, Introduction

Journal Articles

Characterization and Significance of Sulfonylurea Receptors

Linda Siconolfi-Baez, MS, Mary Ann Banerji, MD, Harold E Lebovitz, MD

Diabetes Care 1990;13(Supplement_3):2–8

https://doi.org/10.2337/diacare.13.3.2

Published: 01 August 1990

View article titled, Characterization and Significance of Sulfonylurea Receptors

Journal Articles

Sulfonylureas Why, Which, and How?

Arne Melander, MD, PhD, Harold E Lebovitz, MD, Ole K Faber, MD, PhD

Diabetes Care 1990;13(Supplement_3):18–25

https://doi.org/10.2337/diacare.13.3.18

Published: 01 August 1990

View article titled, Sulfonylureas Why, Which, and How?

Journal Articles

Metabolic Effects of Combination Glipizide and Human Proinsulin Treatment in NIDDM

RoseMarie Pasmantier, MD, Rochelle L Chaiken, MD, Sondra R Hirsch, RN, MS, Harold E Lebovitz, MD

Diabetes Care 1990;13(Supplement_3):42–46

https://doi.org/10.2337/diacare.13.3.42

Published: 01 August 1990

View article titled, Metabolic Effects of Combination Glipizide and Human Proinsulin Treatment in NIDDM

Journal Articles

Combination Insulin-Sulfonylurea Therapy

Harold E Lebovitz, MD, RoseMarie Pasmantier, MD

Diabetes Care 1990;13(6):667–675

https://doi.org/10.2337/diacare.13.6.667

Published: 01 June 1990

View article titled, Combination Insulin-Sulfonylurea Therapy

NARROW

Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations

The Efficacy and Safety of Imeglimin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Sitagliptin Monotherapy

The Efficacy and Safety of Imeglimin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy

Insulin: Potential Negative Consequences of Early Routine Use in Patients With Type 2 Diabetes

Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A Consensus Statement From the American Diabetes Association and the European Association for the Study of Diabetes : Response to Nathan et al.

Point: Visceral Adiposity Is Causally Related to Insulin Resistance

Evaluation of Liver Function in Type 2 Diabetic Patients During Clinical Trials: Evidence that rosiglitazone does not cause hepatic dysfunction

Hyperfiltration in African-American Patients With Type 2 Diabetes: Cross-sectional and longitudinal data

Response to Nagasaka et al: Ketoacidosis-onset type 2 diabetes: clinical features and implicatio

Utility of Untimed Urinary Albumin Measurements in Assessing Albuminuria in Black NIDDM Subjects

Stepwise and Combination Drug Therapy for the Treatment of NIDDM

HLA-DQ Associations Distinguish Insulin-Resistant and Insulin-Sensitive Variants of NIDDM in Black Americans

Insulin Action in Black Americans With NIDDM

Patterns of Glucose and Lipid Abnormalities in Black NIDDM Subjects

Cross-Sectional Analysis of Renal Function in Black Americans With NIDDM

Introduction

Characterization and Significance of Sulfonylurea Receptors

Sulfonylureas Why, Which, and How?

Metabolic Effects of Combination Glipizide and Human Proinsulin Treatment in NIDDM

Combination Insulin-Sulfonylurea Therapy

Email alerts

Journals

Books

Clinical Compendia

News

Other

About

Resources

Email alerts

Journals

Books

Clinical Compendia

News

Other

About

Resources

This Feature Is Available To Subscribers Only